Differential modulation of donor-specific antibodies after B-cell depleting therapies to cure chronic antibody mediated rejection

• Published in: Transplantation Vol. 99; no. 1; p. 63
• Main Authors: Touzot, Maxime, Couvrat-Desvergnes, Grégoire, Castagnet, Stéphanie, Cesbron, Anne, Renaudin, Karine, Cantarovich, Diego, Giral, Magali
• Format: Journal Article
• Language: English
• Published: United States 01.01.2015
• Subjects: Adolescent; Adult; Aged; Antibodies, Monoclonal, Murine-Derived - adverse effects; Antibodies, Monoclonal, Murine-Derived - therapeutic use; Autoantibodies - blood; B-Lymphocytes - drug effects; B-Lymphocytes - immunology; Biomarkers - blood; Biopsy; Boronic Acids - adverse effects; Boronic Acids - therapeutic use; Bortezomib; Child; Female; France; Graft Rejection - blood; Graft Rejection - diagnosis; Graft Rejection - immunology; Graft Rejection - therapy; Graft Survival - drug effects; HLA Antigens - immunology; Humans; Immunosuppressive Agents - adverse effects; Immunosuppressive Agents - therapeutic use; Kidney Transplantation - adverse effects; Male; Middle Aged; Plasmapheresis; Pyrazines - adverse effects; Pyrazines - therapeutic use; Retrospective Studies; Rituximab; Time Factors; Treatment Outcome; Young Adult; France

Donor-specific antibodies (DSA) are considered as reliable biomarkers for antibody-mediated rejection (ABMR) diagnosis. However, it is unclear whether DSA monitoring is necessary and could predict graft outcome after antirejection treatment. We analyzed 28 non-sensitized kidney transplant patients w...